We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$7.1B
AUM Growth
-$1.16B
Cap. Flow
-$291M
Cap. Flow %
-4.1%
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
3
MDT icon
Medtronic
MDT
+$115M
4
DXCM icon
DexCom
DXCM
+$83.5M
5
LIVN icon
LivaNova
LIVN
+$79.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$149M
2
GILD icon
Gilead Sciences
GILD
+$133M
3
ONEM
1Life Healthcare
ONEM
+$129M
4
BEAM icon
Beam Therapeutics
BEAM
+$119M
5
SNY icon
Sanofi
SNY
+$96.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.83%
3 Consumer Staples 0.3%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNMK
26
DELISTED
GenMark Diagnostics, Inc
GNMK
$85.8M 1.21%
3,589,342
-948,058
-21% -$17.6M
LIVN icon
27
LivaNova
LIVN
$4.41B
$82.6M 1.16%
+1,119,830
New +$79.9M
RPTX
28
DELISTED
Repare Therapeutics
RPTX
$81.8M 1.15%
2,665,496
+17,800
+0.7% +$605K
NGM
29
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$80M 1.13%
+2,751,815
New +$77M
DXCM icon
30
DexCom
DXCM
$33.7B
$79.9M 1.13%
+889,832
New +$83.5M
RGNX icon
31
Regenxbio
RGNX
$619M
$79.8M 1.12%
2,340,313
+216,821
+10% +$9.25M
TCRR
32
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$79.7M 1.12%
3,610,788
+777,900
+27% +$21.2M
IMGN
33
DELISTED
Immunogen Inc
IMGN
$78.5M 1.11%
9,688,066
-840,113
-8% -$6.86M
EPZM
34
DELISTED
Epizyme, Inc
EPZM
$76.9M 1.08%
8,824,366
-625,939
-7% -$6.48M
AKRO
35
DELISTED
Akero Therapeutics
AKRO
$72.9M 1.03%
2,513,746
+191,189
+8% +$5.79M
ALXO icon
36
ALX Oncology
ALXO
$283M
$72.2M 1.02%
978,600
+18,200
+2% +$1.43M
NVRO
37
DELISTED
NEVRO CORP.
NVRO
$72.1M 1.02%
516,795
+72,886
+16% +$11.9M
AVIR icon
38
Atea Pharmaceuticals
AVIR
$437M
$71.5M 1.01%
1,158,082
-1,073,628
-48% -$72.5M
CLDX icon
39
Celldex Therapeutics
CLDX
$3.18B
$69.8M 0.98%
3,387,788
+676,172
+25% +$15.5M
CI icon
40
Cigna
CI
$73.4B
$67.7M 0.95%
280,057
-103,036
-27% -$23M
SLQT icon
41
SelectQuote
SLQT
$95.3M
$59.2M 0.83%
2,005,054
+160,335
+9% +$4.2M
NGNE icon
42
Neurogene
NGNE
$758M
$50.7M 0.71%
205,878
-715
-0.3% -$183K
CRL icon
43
Charles River Laboratories
CRL
$14.2B
$48.3M 0.68%
+166,679
New +$46.3M
NUVB icon
44
Nuvation Bio
NUVB
$2.45B
$47.5M 0.67%
+4,541,009
New +$50.8M
ELV icon
45
Elevance Health
ELV
$86.6B
$46.8M 0.66%
130,405
-113,927
-47% -$36.6M
PRTA icon
46
Prothena Corp
PRTA
$467M
$46.6M 0.66%
+1,857,072
New +$34.9M
ICUI icon
47
ICU Medical
ICUI
$4.38B
$46M 0.65%
224,154
-17,300
-7% -$3.65M
BIIB icon
48
Biogen
BIIB
$32.7B
$45.6M 0.64%
162,847
-53,400
-25% -$14.4M
KLRS
49
Kalaris Therapeutics
KLRS
$97.6M
$45.5M 0.64%
84,504
-16,609
-16% -$14M
GMAB icon
50
Genmab
GMAB
$21B
$43.7M 0.62%
+1,332,212
New +$50.1M
1
2
3 4 5

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2021 Portfolio in Review

As of Q1 2021, Redmile Group held 104 positions worth $7.1B, down 14% from $8.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $291M in Q1 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was AbbVie, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Seagen Inc. Common Stock worth $130M.

  • Redmile Group's largest Q1 2021 buy was Seagen Inc. Common Stock: 937,045 shares worth $130M.
  • Redmile Group added most to Fate Therapeutics in Q1 2021, an estimated $31.4M increase.
  • Redmile Group's biggest Q1 2021 reduction was 1Life Healthcare, cutting an estimated $129M.
  • Redmile Group fully exited AbbVie in Q1 2021, selling an estimated $149M.
  • Redmile Group's ten largest holdings make up 42% of its $7.1B portfolio in Q1 2021.
  • Redmile Group opened 17 new positions and closed 18 in Q1 2021.
  • Redmile Group's portfolio value fell 14% quarter-over-quarter to $7.1B.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.